Faro AI Raises $37.3M to Scale Clinical Trial Agents

Faro has raised a $37.3M Series B to expand the structured data and AI infrastructure it sells into clinical development. Merck Global Health Innovation Fund and S32 co-led the financing, with all existing investors participating and Ankona Capital joining as a new backer.

The round matters because Faro is trying to move clinical-development AI beyond document generation. Its system represents the intent, relationships, and constraints behind a study so software agents can reason across workflows that remain connected even when separate teams and systems handle them.

The next proof is operational. Pharmaceutical companies do not need another fluent draft if the system loses track of why an endpoint, assessment, visit, or eligibility rule was selected. Faro now has more capital to show that structured intent can support faster work without weakening traceability or human oversight.

What Happened

Faro announced the Series B on August 26, 2026. Merck Global Health Innovation Fund and S32 co-led the round, while General Catalyst, Northpond Ventures, Polaris Partners, PTX Capital, and Zetta returned. Ankona Capital participated as a new investor. Faro did not disclose its valuation, individual check sizes, or new board rights.

The financing brings Faro's disclosed capital to at least $75.6M based on its official announcements. The company reported $18.3M across seed and Series A financing in 2022, including a $15M Series A led by the firm now known as S32. General Catalyst then led a $20M financing in 2023, followed by the current $37.3M Series B.

Faro plans to use the new capital to expand its agentic AI capabilities and support customers deploying agents across clinical-development organizations. The company framed protocols and clinical documents as outputs from a broader structured model, rather than the final boundary of the product.

From Clinical Documents to Structured Intent

Clinical development is full of handoffs. Scientific objectives become endpoints, endpoints shape assessments, assessments create visits, visits affect patients and sites, and the study design eventually has to move into operational systems. A document can describe those decisions without preserving their relationships in a form software can reliably use.

Faro's thesis is that clinical-development intent should exist as structured data. Its proprietary ontology and data models are designed to represent scientific, medical, regulatory, and operational concepts in a machine-readable form. That foundation supports study design, protocol authoring, and workflow automation across systems such as EDC builds, site budgets, APIs, and USDM JSON.

This is a more demanding product problem than generating text. A protocol draft can look polished while carrying a misunderstanding that later reaches data collection, site operations, or regulatory work. Structured intent creates the possibility of tracing an output back to the study decisions that produced it, while keeping clinical and operational experts accountable for review.

Why the Investor Mix Matters

The co-lead investors reflect the two sides of Faro's commercial problem. Merck GHI Fund invests in digital-health and data-science companies that can improve biopharmaceutical operations, while S32 backs companies across AI, computational biology, infrastructure, and enterprise technology. Faro needs both clinical-development credibility and the engineering capacity to turn a complex domain model into reliable software.

The returning investors also show continued support across multiple product stages. General Catalyst led Faro's 2023 round, while Northpond Ventures, Polaris Partners, S32, and Zetta were part of the earlier financing history. PTX Capital is also returning, and Ankona's new participation adds an investor focused on scaling B2B software after product-market fit.

That syndicate does not make agentic clinical development inevitable. It does give Faro capital and relationships to test its platform inside organizations where the cost of a weak workflow is measured in rework, delayed studies, and decisions that have to survive scientific and regulatory scrutiny.

Customer Evidence and the Boundary of the Claims

Faro says its platform is used by six of the world's ten largest pharmaceutical companies. That is a company-reported metric, and the Series B announcement does not identify every customer or provide audited deployment results. Public relationships still offer useful evidence that Faro has moved beyond a laboratory product.

Recursion disclosed an agreement with Faro to use the platform for clinical protocol design and potentially automate downstream work such as electronic data-capture builds. Faro also announced a Bristol Myers Squibb collaboration in March 2026 and has described work spanning protocol design, document authoring, and operational workflows.

The company also reports enterprise controls including SOC 2 Type II and ISO 27001:2022 on its Trust Center. Those controls matter because pharmaceutical buyers have to evaluate data security, governance, system validation, and human oversight alongside product capability. They are not proof that every AI output is correct, but they are part of the permission structure required to deploy software into regulated work.

What the Series B Has to Prove

Faro's opportunity is larger than helping teams write protocols faster. If a structured study definition can travel through authoring, schedule design, data capture, budgeting, vendor specifications, and other downstream workflows, clinical-development teams can reduce the repeated translation and reconciliation that creates delay and error.

The hard part is preserving context as automation expands. An agent operating across clinical development must know which decisions are fixed, which can change, what evidence supports them, and when a human expert must intervene. Speed has value only when the system can explain what it did and the accountable team can review the result.

The $37.3M Series B gives Faro more room to build and deploy that infrastructure. The market test will be whether pharmaceutical and biotechnology customers expand from individual protocol tools into connected agentic workflows, and whether those workflows improve quality and efficiency without turning a fluent mistake into a faster operating problem.